TDC
CORT icon

Thompson Davis & Co’s Corcept Therapeutics CORT Stock Holding History

Thompson Davis & Co’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		$2K Hold
125
– – ﹤0.01% 657
2018
Q2 		$2K Hold
125
– – ﹤0.01% 605
2018
Q1 		$2K Buy
+125
New +$2.32K 0.01% 561

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Thompson Davis & Co's CORT Position: Q3 2018 in Review

Thompson Davis & Co held its Corcept Therapeutics (CORT) position steady in Q3 2018 at 125 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #657.

Thompson Davis & Co first reported a position in CORT in Q1 2018 and has held it in 3 quarters since. 207 funds tracked by Wall St. Rank hold CORT as of Q3 2018.

  • Thompson Davis & Co held 125 shares of Corcept Therapeutics worth $2K as of Q3 2018.
  • Thompson Davis & Co left its Corcept Therapeutics share count unchanged in Q3 2018.
  • Corcept Therapeutics made up ﹤0.01% of Thompson Davis & Co's portfolio in Q3 2018, its #657 holding.
  • Thompson Davis & Co first reported a position in Corcept Therapeutics in Q1 2018 and has held it in 3 quarters since.
  • 207 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q3 2018.

Based on Thompson Davis & Co's 13F filing for Q3 2018, filed 14 Nov 2018.